What is Angiochem?
Founded in 2003, Angiochem operates at the intersection of advanced pharmacology and neurology. The company specializes in the discovery and development of breakthrough peptide drug conjugates, a sophisticated class of therapeutics designed to cross the blood-brain barrier with high precision. By focusing on high-unmet-need neurological diseases, Angiochem has established itself as a critical player in the biotech sector, utilizing its proprietary technology platform to address conditions that have historically proven resistant to conventional drug delivery methods. Its market position is defined by a rigorous commitment to clinical-stage validation and the pursuit of transformative medical solutions.
How much funding has Angiochem raised?
Angiochem has raised a total of $7.5M across 1 funding round:
Series C
$7.5M
Series C (2018): $7.5M, investors not publicly disclosed
Key Investors in Angiochem
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Angiochem?
With the recent influx of capital, Angiochem is expected to prioritize the advancement of its lead candidates through critical clinical trial phases. The strategic deployment of these funds will likely focus on scaling operational capacity, enhancing manufacturing processes for its peptide drug conjugates, and expanding its intellectual property portfolio. As the company transitions further into late-stage development, the focus will shift toward regulatory milestones and potential commercialization partnerships. This major enterprise-level funding serves as a catalyst for long-term growth, enabling the firm to solidify its competitive advantage in the global neuro-therapeutics market while navigating the complexities of drug development and clinical efficacy testing.
See full Angiochem company page
